1.How to secure the connection between thoracostomy tube and drainage system?
Ka Ki Pat LI ; Kit Shing John WONG ; Yau Hang Henry WONG ; Cheng Lok KA ; So Ling FUNG ; Lau Leung CHU ; Kam Wah CHAK
World Journal of Emergency Medicine 2014;5(4):259-263
BACKGROUND: Thoracostomy tube insertion is one of the common bedside procedures in emergency medicine and many acute specialties. Dislodgement of thoracostomy tube from the connection tube of chest drainage system is an important problem with potential complications such as contamination, infection and pneumothorax. Besides, mere loosening can also lead to malfunction. It is a common practice to tape the connection of the system. This study aimed to evaluate the materials and methods of connection of chest drain system to minimize drainage dislodgement. METHODS: We conducted an experimental study to assess the tightness of the connection with various taping materials and methods. We selected three commonly used adhesive materials (3M?Transpore? Medical tape, 3M? Micropore? Medical tape, 3M? Soft Cloth Tape on Liner) and three different methods (cross method, straight method, nylon band) to secure the junction between the thoracostomy tube and the bi-conical adaptor in the drainage system. The measured outcome was the weight causing visible loosening of the junction between thoracotomy tube and the adaptor. RESULTS: For each taping material and taping method, 10 trials were performed. The median weight required to disconnect the junction is 26.22 lb for Transpore?, 31.29 lb for Micropore? and 32.44 lb for Soft Cloth Tape on Liner. A smaller force was required to disconnect if Transpore? is used (P<0.001). There was no statistical significant difference between Micropore? and Soft Cloth Tape on Liner (P=0.98). The median disconnecting force is 32.44 lb for straight taping method, 40.55 lb for cross taping method and 21.15 lb for plastic band. The cross-taping method was the more secure method (P<0.0001 when compared with plastic band) (P=0.033 when compared with straight method). CONCLUSION: Cross-taping is the most secure method among the tested varieties in connecting the thoracostomy tube to the chest drainage system. Transpore? is not a recommended material for thoracostomy tube taping.
2.Echocardiographic mapping of left ventricular resynchronization during cardiac resynchronization therapy procedures.
Ngai-Yin CHAN ; Chi-Chung CHOY ; Kar-Chun CHEUNG ; Chun-Leung LAU ; Ying-Keung LO ; Pui-Shan CHU ; Ho-Chuen YUEN ; Suet-Ting LAU ; Yuen-Choi CHOI
Chinese Medical Journal 2010;123(13):1645-1651
BACKGROUNDCardiac resynchronization therapy (CRT) is an effective electrical therapy for patients with moderate to severe heart failure and cardiac dyssynchrony. This study aimed to investigate the degree of acute left ventricular (LV) resynchronization with biventricular pacing (BVP) at different LV sites and to examine the feasibility of performing transthoracic echocardiography (TTE) to quantify acute LV resynchronization during CRT procedure.
METHODSFourteen patients with NYHA Class III-IV heart failure, LV ejection fraction < or = 35%, QRS duration > or = 120 ms and septal-lateral delay (SLD) > or = 60 ms on tissue Doppler imaging (TDI), underwent CRT implant. TDI was obtained from three apical views during BVP at each accessible LV site and SLD during BVP was derived. Synchronicity gain index (Sg) by SLD was defined as (1 + (SLD at baseline--SLD at BVP)/SLD at baseline).
RESULTSSeventy-two sites were studied. Positive resynchronization (R+, Sg > 1) was found in 42 (58%) sites. R+ was more likely in posterior or lateral than anterior LV sites (66% vs. 36%, P < 0.001). Concordance of empirical LV lead implantation sites and sites with R+ was 50% (7/14).
CONCLUSIONSThe degree of acute LV resynchronization by BVP depends on LV lead location and empirical implantation of LV lead results in only 50% concordance with R+. Performing TTE during CRT implantation is feasible to identify LV sites with positive resynchronization.
Aged ; Cardiac Resynchronization Therapy ; methods ; Echocardiography ; methods ; Female ; Heart Failure ; therapy ; Humans ; Male ; Middle Aged ; Ventricular Dysfunction, Left ; therapy
3.Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer’s Disease Patients in Asia
Kee Hyung PARK ; YoungSoon YANG ; Christopher CHEN ; Yong S. SHIM ; Jacqueline C. DOMINGUEZ ; Chan-Nyoung LEE ; Kyunghun KANG ; Hee-Jin KIM ; Seul-Ki JEONG ; Jee Hyang JEONG ; Zhen HONG ; Soo Jin YOON ; Zhen-Xin ZHANG ; Eun-Joo KIM ; Jae-Won JANG ; Yansheng LI ; Yun XU ; Yu-Te LIN ; Qiumin QU ; Chaur-Jong HU ; Chih-Ho CHOU ; Dongsheng FAN ; Nagaendran KANDIAH ; Yuan-Han YANG ; Chi-ieong LAU ; Leung-Wing CHU ; Huali WANG ; San JUNG ; Seong Hye CHOI ; SangYun KIM
Journal of Clinical Neurology 2021;17(3):376-384
Background:
and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer’s disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia.
Methods:
This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50–90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation,treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS).
Results:
Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test–Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6±14.1% (mean±standard deviation) on the VAS.
Conclusions
In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function.
4.Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer’s Disease Patients in Asia
Kee Hyung PARK ; YoungSoon YANG ; Christopher CHEN ; Yong S. SHIM ; Jacqueline C. DOMINGUEZ ; Chan-Nyoung LEE ; Kyunghun KANG ; Hee-Jin KIM ; Seul-Ki JEONG ; Jee Hyang JEONG ; Zhen HONG ; Soo Jin YOON ; Zhen-Xin ZHANG ; Eun-Joo KIM ; Jae-Won JANG ; Yansheng LI ; Yun XU ; Yu-Te LIN ; Qiumin QU ; Chaur-Jong HU ; Chih-Ho CHOU ; Dongsheng FAN ; Nagaendran KANDIAH ; Yuan-Han YANG ; Chi-ieong LAU ; Leung-Wing CHU ; Huali WANG ; San JUNG ; Seong Hye CHOI ; SangYun KIM
Journal of Clinical Neurology 2021;17(3):376-384
Background:
and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer’s disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia.
Methods:
This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50–90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation,treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS).
Results:
Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test–Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6±14.1% (mean±standard deviation) on the VAS.
Conclusions
In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function.